Skip to content

The comparison of the effect of garsin and metronidazole on bacterial vaginosis

The comparison of the effects of garsin tablet ( made of garlic ) and metronidazole tablet on treatment of bacterial vaginosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201207153226N4
Enrollment
140
Registered
2013-12-20
Start date
2013-12-16
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacterial vaginosis infection. Vulvovaginal ulceration and inflammation in diseases classified elsewhere

Interventions

Intervention 1: One group Metronidazole 250 mg tablet, twice daily 500 mg (every 12 hours) with food for 7 days. Intervention 2: the other group Garsin 500 mg tablet, twice daily 1000 mg (every 12 hou
Treatment - Drugs
One group Metronidazole 250 mg tablet, twice daily 500 mg (every 12 hours) with food for 7 days
the other group Garsin 500 mg tablet, twice daily 1000 mg (every 12 hours) with meal for 7 days.

Sponsors

The International Branch of Shahid Beheshti university of medical sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 44 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: married women; aged 18-44 years old, with single partner whose infection with bacterial vaginosis is diagnosed through clinical Amsel criteria and labratory Nugent criteria ( Patients identified with cervicitis tricamona or candidiadis infections are excluded from the study); they should not use IUD. Also they should not use antibiotics, vaginal drug or immunosuppressive drugs in recent fourteen days. During clinical examination they should not have any breakthrough bleeding or menstrual period. They should not be pregnant, lactating or menopause. They should not have mental retardation or known physical disease; suffering from thyroid disease; coagulation disorders; diabetes and autoimmune diseases. Exclusion criteria: not tolerate any form of drug or discontinuation for at least 48 hours, become pregnant during treatment, forcing the use of antibiotics during treatment.

Exclusion criteria

Exclusion criteria:

Design outcomes

Secondary

MeasureTime frame
Bacterial vaginosis infection. Timepoint: Before the intervention, 7-10 days after beginning treatment. Method of measurement: Clinical complaint questionnaires are completed by samples (itching, burning, abnormal discharge, smelly discharge).

Primary

MeasureTime frame
Amsel criteria. Timepoint: Before the intervention, 7-10 days after begining of treatment. Method of measurement: Amsel have 4 criteria: key cells in the wet mount vaginal sample Vaginal dyscharge thin and white uniform - gray, white or yellowish, Vaginal pH equal to or greater than 4/5, positive whiff test. If at least 3 of the 4 cases mentioned above is positive, bacterial vaginosis is brought on .;Nugent criteria. Timepoint: Before the intervention, 7-10 days after beginning treatment. Method of measurement: These criteria are based on the observation lactobacil and other morphotype (Gardnerella vaginalis and Mobiluncus forms) are rated from zero to 10 points, a total score of 7-10 means abnormal vaginal flora (bacterial vaginosis), grades 4-6 (Intermediate) in this study means abnormal vaginal flora. normal flora score is 0-3.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarnaz Mohammadzadeh

The International Branch of Shahid Beheshti university of medical sciences

farnaz.mohammadzade@gmail.com; sbnmf@sbmu.ac.ir+98 21 8865 5366

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026